| Literature DB >> 12471628 |
Annika Auranen1, Amanda B Spurdle, Xiaoqing Chen, Julian Lipscombe, David M Purdie, John L Hopper, Adele Green, Catherine S Healey, Karen Redman, Alison M Dunning, Paul D Pharoah, Douglas F Easton, Bruce A J Ponder, Georgia Chenevix-Trench, Karen L Novik.
Abstract
The BRCA2 372 HH genotype defined by the BRCA2 N372H nonconservative amino acid substitution polymorphism was recently reported to be associated with a small increased risk of breast cancer. We investigated whether this polymorphism was associated with ovarian cancer risk by conducting British and Australian case-control comparisons in parallel, including a total sample of 1,121 ovarian cancer cases and 2,643 controls. There was no difference in genotype frequency between control groups from the 2 studies (p = 0.9). The HH genotype was associated with an increased risk of ovarian cancer in both studies, and the risk estimate for the pooled studies was 1.36 (95% CI 1.04-1.77, p = 0.03). There was also a suggestion that this risk may be greater for ovarian cancers of the serous subtype for both studies, with an OR (95% CI) of 1.66 (1.17-2.54) for the 2 studies combined (p = 0.005). The BRCA2 372 HH genotype appears to be associated with an increased risk of ovarian cancer of a similar magnitude to that reported for breast cancer. Copyright 2002 Wiley-Liss, Inc.Entities:
Mesh:
Substances:
Year: 2003 PMID: 12471628 DOI: 10.1002/ijc.10814
Source DB: PubMed Journal: Int J Cancer ISSN: 0020-7136 Impact factor: 7.396